Search
forResearch 10 of 1000+
- LB1139 AMP-303 injectable treatment for androgenetic alopecia: A multicenter, randomized, placebo-controlled feasibility study of a novel polysaccharide
- 453 Signaling by Senescent Melanocytes Induces New Hair Growth and Informs Hair Growth-Activating Injectable for Androgenetic Alopecia
- Emerging pharmacotherapies for Androgenetic Alopecia
- Association of premature hair graying with family history, smoking, and obesity: A cross-sectional study
- A Screening Study on Dermatoses in Pregnancy
- Mechanistic Aspects of African Hair Relaxation
- Alopecia areata & periodontal diseases- A connecting link: A review
- Convergent Regenerative Strategies in PM&R for Musculoskeletal and Hair Restoration: Integration of PRP, Exosomes, and Physical Modalities
- Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines
- Updates in the understanding and treatments of skin & hair disorders in women of color
Community 10 of 89
- New Hair Loss Cure: AMP-303 Is Back. It’s what PP405 should have been.
- Proof DHT is not the main cause of hair loss. TRPS1 Gene and Protein might be. PP405 won’t work. AMP-303 might!
- Why there are no updates from Amplifica about SCUBE3 & AMP-303?
- Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
- Amplifica AMP-303 study results are expected late this summer
- Amplifica and AMP-303 clinical phase 1
- Most Promising Future Hair Loss Treatments In 2026
- Amplifica: Hope or Cope? A Review of Their Pipeline
- Update on Amplifica (new drugs) and Engraft (new hair transplant technology)
- Which 2026 hair‑loss treatments have the strongest evidence so far? (minoxidil/finasteride vs. clascoterone, PP405, Re:You’s NV‑623/624, AMP‑303, RU58841)
Learn
— no results
Try a deeper search in learn →